SCHEMBL10255978

SCHEMBL10255978

NC[C@@H](C(N)=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 6/20 0.53
GABBR1 Q9UBS5 6/20 0.53
LMNA P02545 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP1A2 P05177 2/20 0.53
THRB P10828 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP3A4 P08684 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
NFKB1 P19838 1/20 0.53
DRD3 P35462 1/20 0.53
BLM P54132 1/20 0.53
TSHR P16473 1/20 0.53
MAPT P10636 1/20 0.47
PMP22 Q01453 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826506 0.85 GABBR2 (0.46) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL31344403 0.84 GABBR2 (0.58) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL5860866 0.84 GABBR2 (0.58) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL23564521 0.82 FFAR2 (0.48) GABBR2GABBR1LMNACYP2C9CYP1A2
Hydrochloric Acid SCHEMBL191271 0.82 GABBR2 (0.56) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL8217885 0.82 BRD4 (0.53) GABBR2GABBR1LMNACYP2C9CYP1A2
Hydrochloric Acid SCHEMBL191270 0.82 GABBR2 (0.56) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL4452221 0.82 CYP2C9 (0.49) GABBR2GABBR1LMNACYP2C9CYP1A2
SCHEMBL3253687 0.82 TAAR1 (0.52) LMNACYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL8919457 0.81 CYP2C9 (0.44) GABBR2GABBR1LMNACYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012135750-A1 COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE GENENTECH, INC. (US) 2012-10-04 WO disclosed
WO-2012135759-A1 COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE GENENTECH, INC. (US) 2012-10-04 WO disclosed
WO-2012135781-A1 COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE GENENTECH, INC. (US) 2012-10-04 WO disclosed
WO-2012135753-A1 COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE GENENTECH, INC. (US) 2012-10-04 WO disclosed
EP-2402325-A2 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors Array Biopharma, Inc. (US) 2012-01-04 EP disclosed
EP-2399909-A1 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as akt protein kinase inhibitors Array Biopharma, Inc. (US) 2011-12-28 EP disclosed
EP-2049501-B1 HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2011-09-14 EP disclosed